Stock MNOV MEDICINOVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MediciNova, Inc.

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.31 USD -0.76% Intraday chart for MediciNova, Inc. -5.76% -12.67%
Mar. 27 MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan CI
Mar. 12 Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 295.9 236.3 131.4 100.5 73.57 64.25 - -
Enterprise Value (EV) 1 295.9 176.3 131.4 100.5 73.57 64.25 64.25 64.25
P/E ratio -22.5 x -17 x -12.8 x -7.07 x -8.82 x -5.7 x -5.46 x -5.46 x
Yield - - - - - - - -
Capitalization / Revenue - - 32.6 x - 73.6 x - - -
EV / Revenue - - 32.6 x - 73.6 x - - -
EV / EBITDA - -16,692,748 x - - - - - -
EV / FCF -32,390,079 x -21,754,779 x -13,967,179 x -7,784,172 x - - - -
FCF Yield -0% -0% -0% -0% - - - -
Price to Book 3.95 x 3.32 x - - - - - -
Nbr of stocks (in thousands) 43,906 44,928 49,043 49,046 49,046 49,046 - -
Reference price 2 6.740 5.260 2.680 2.050 1.500 1.310 1.310 1.310
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 4.038 - 1 - - -
EBITDA - -14.16 - - - - - -
EBIT 1 -14.03 -14.18 -10.22 -14.63 -9.9 -11.3 -11.7 -12.1
Operating Margin - - -253.02% - -990.03% - - -
Earnings before Tax (EBT) 1 -12.93 -13.86 -10.13 -14.07 -8.568 -11.3 -11.7 -12.1
Net income 1 -12.94 -13.85 -10.13 -14.07 -8.572 -11.3 -11.7 -12.1
Net margin - - -251% - -857.15% - - -
EPS 2 -0.3000 -0.3100 -0.2100 -0.2900 -0.1700 -0.2300 -0.2400 -0.2400
Free Cash Flow -9.136 -10.86 -9.41 -12.92 - - - -
FCF margin - - -233.07% - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.0375 - - - - - - - 1 - - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -3.602 -2.103 -3.41 -4.09 -3.897 -3.231 -2.963 -3.3 -1.147 -2.49 -2.6 -2.8 -2.9 -3
Operating Margin -9,605.17% - - - - - - - -114.69% - - - - -
Earnings before Tax (EBT) 1 -3.579 -2.081 -3.386 -4.029 -3.652 -2.999 -2.918 -2.872 -0.7231 -2.056 -2.6 -2.8 -2.9 -3
Net income 1 -3.579 -2.083 -3.386 -4.029 -3.652 -3.001 -2.918 -2.872 -0.7231 -2.059 -2.6 -2.8 -2.9 -3
Net margin -9,544.45% - - - - - - - -72.31% - - - - -
EPS 2 -0.0700 -0.0400 -0.0700 -0.0800 -0.0700 -0.0600 -0.0600 -0.0600 -0.0100 -0.0400 -0.0500 -0.0600 -0.0600 -0.0600
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/12/21 2/16/22 5/12/22 8/11/22 11/10/22 2/16/23 5/11/23 8/9/23 11/9/23 2/15/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 60 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -9.14 -10.9 -9.41 -12.9 - - - -
ROE (net income / shareholders' equity) -17.5% -19% - - - - - -
ROA (Net income/ Total Assets) -16.5% -17.9% - - - - - -
Assets 1 78.22 77.31 - - - - - -
Book Value Per Share 1.710 1.580 - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.01 0.04 0.03 0.01 - - - -
Capex / Sales - - 0.71% - - - - -
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.31 USD
Average target price
17 USD
Spread / Average Target
+1,197.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDICINOVA, INC. Stock MediciNova, Inc.
-12.67% 64.25M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MNOV Stock
  4. Financials MediciNova, Inc.